Reduction in headache was a consistent finding across the studies using GLP-1 RAs
The 11.2% discontinuation rate at highest dose is similar to tirzepatide (6-9%) and better than earlier GLP-1 medications
While the overall incidence was lower than previously reported rates of 30%50% (Jones et al., 2018), this discrepancy may be attributable to the subjective nature of symptom assessment in the included studies, as many lacked objective quantitative methods (Kong et al., 1998)
Federal rules ban Medicare Part D -- which helps cover prescription drug costs -- from covering drugs solely to treat obesity, but a new federal pilot bridge program approved by Health and Human Services Secretary Robert F
Acta Dermatovenerologica Croatica 24:9595 Trichot C (2019) Regulation of human T helper cell diversity: from in vitro dendritic cell-based mechanisms to candidate biomarkers in atopic dermatitis
Known research-associated effects Tirzepatide research has documented a well-characterized side effect profile
